Weight-Loss Medications vs. Peptides for Weight Loss
By Charles Kamen, MD, board-certified neurologist
The weight-loss medication landscape has evolved dramatically. GLP-1 medications — semaglutide (a single-hormone GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist) — have dominated headlines and clinical conversations. But another category, targeted peptide protocols, is generating serious scientific interest for specific patient populations.
Dr. Kamen regularly sees patients confused about the difference. This guide cuts through the noise.
What Are Weight Management Medications?
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone secreted by the gut in response to food intake. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. [1]
GLP-1 receptor agonists are synthetic molecules that activate the GLP-1 receptor with a longer half-life than endogenous GLP-1. They were originally developed for Type 2 diabetes management; the weight-loss indication followed the observation of consistent body-weight reduction in clinical trials. [2]
- Semaglutide: Weekly subcutaneous injection. GLP-1 mono-agonist. Average weight loss in STEP trials: 15-17% of body weight at 68 weeks. [3]
- Tirzepatide: Weekly subcutaneous injection. Dual GIP/GLP-1 agonist. Average weight loss in SURMOUNT trials: 20-22% of body weight at 72 weeks. [4]
What Are Targeted Peptide Protocols?
"Peptide protocols" for weight loss refer to combinations of peptides that address distinct physiological pathways — not a single drug, but a multi-targeted approach. Commonly used peptides include:
- AOD-9604: A fragment of human growth hormone (hGH 177-191) studied for lipolytic (fat-burning) activity. No FDA approval; available through compounding pharmacies. [5]
- 5-Amino-1MQ: A small molecule that inhibits methionine aminopeptidase 2 (MetAP2), reducing fat accumulation in preclinical models. Early human data are promising but limited. [6]
- Semaglutide (when used as part of a peptide protocol): the same GLP-1 molecule, but may be combined with other peptides in customized protocols.
- Growth hormone secretagogues (e.g., CJC-1295 / Ipamorelin): used to support lean body mass preservation during caloric restriction. [7]
Key Differences
The fundamental distinction is that weight-loss medications work primarily through appetite suppression, while peptide protocols often attempt to address multiple pathways simultaneously — including lipolysis, growth hormone support, and metabolic rate.
- GLP-1 medications: Central appetite suppression via hypothalamic signaling. Proven, standardized dosing. FDA-approved for weight loss (semaglutide, tirzepatide) and for type 2 diabetes.
- Peptide protocols: Multi-pathway approach. Customizable to individual physiology. Not FDA-approved for weight loss. Less standardized; requires physician supervision.
- Combination approaches: Some clinicians, including Dr. Kamen, use weight-loss medications in combination with supporting peptides for patients who plateau or struggle with muscle preservation.
Side Effect Comparison
Both categories carry gastrointestinal side effects — nausea, constipation, and delayed gastric emptying are common with weight-loss medications. Peptide protocols generally have a lower GI burden, though injection site reactions and fatigue can occur. [8]
Important: weight-loss medications carry an FDA boxed warning for thyroid C-cell tumors in rodents (relevance to humans is debated). No similar signal has been identified for lipolytic peptides or 5-Amino-1MQ. [9]
Key Takeaways
- GLP-1 medications (semaglutide and tirzepatide) are FDA-approved weight-loss medications with robust clinical trial data
- Peptide protocols offer multi-pathway support but are not FDA-approved for weight loss
- Peptide protocols may be preferable for patients seeking to avoid pharmaceutical GLP-1 agents or who have plateaued on them
- Both approaches require physician supervision — self-administration is not safe
- Dr. Kamen designs individualized weight management protocols combining the most appropriate tools for each patient
Common Questions
Can I switch from a weight-loss medication to a peptide protocol?
Yes. Some patients transition after reaching their goal weight on weight-loss medication therapy to support maintenance. Others prefer to start with peptide protocols and escalate to weight-loss medication only if needed. Dr. Kamen reviews the full history at consultation.
Does insurance cover these treatments?
FDA-approved GLP-1 medications (semaglutide, tirzepatide) may be covered by insurance for their approved indications. Compounded peptides are typically not covered by insurance. Our team provides documentation to support coverage appeals where appropriate.
What about semaglutide vs. tirzepatide?
Tirzepatide has demonstrated superior weight loss in head-to-head trials, likely due to its dual GIP/GLP-1 agonism. However, individual response varies, and cost and availability may influence access.
Both weight-loss medications and peptide protocols represent legitimate tools in a comprehensive weight management protocol. The right choice depends on your medical history, weight loss goals, and response to treatment. Explore our weight management protocols or schedule a consultation with Dr. Kamen to discuss your options.
References
- Drucker DJ. Cell Metab. 2022;35(4):587-605.
- Gibbons C, Blundell J, et al. Diabetes Obes Metab. 2021;23(2):581-588. (GLP-1 receptor agonist effects on energy intake, appetite, and control of eating).
- Wilding JPH, et al. N Engl J Med. 2021;384:989-1002.
- Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. (SURMOUNT-1, dual GIP/GLP-1 in obesity).
- Ng FM, et al. Horm Res. 2000;53(6):274-278. (Metabolic studies of AOD9604, a synthetic lipolytic domain of human growth hormone).
- Huang SM, et al. Nat Chem Biol. 2020;16(5):537-546.
- Nass R, et al. Ann Intern Med. 2008;149(9):601-611. (Oral ghrelin mimetic on body composition in healthy older adults, RCT).
- France NL, Syed YY. Drugs. 2024;84(2):227-238. (Tirzepatide: a review, including gastrointestinal tolerability).
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023.
- Aronne LJ, et al. N Engl J Med. 2025;393:26-36. (SURMOUNT-5, dual GIP/GLP-1 vs semaglutide head-to-head).
- Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. (STEP 1 trial, semaglutide).
Physician-Led Peptide Care in Las Vegas
Whether a GLP-1 medication, a targeted peptide protocol, or a combination is appropriate is a clinical decision that depends on your labs, medical history, and goals. At our physician-led peptide clinic in Las Vegas, every protocol is designed, prescribed, and monitored by Dr. Kamen, a board-certified neurologist.
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.